Nanordica Medical aims to significantly improve wound care quality

Research and development company Nanordica Medical is working on novel antibacterial wound care products several times more effective than those currently on the market. If everything goes according to plan, the products will be available in all Estonian hospitals and pharmacies as of 2023.

“To enter the market, we first have to comply with all the regulatory requirements and obtain all the necessary certificates. We are currently teaming up with North Estonia Medical Centre to plan clinical trials, and our first clients to be involved in the trials will be patients with wound infections,” says the company’s Head of Product Development Anna-Liisa Kubo.

Nanordica developed novel technology that has the potential to solve the issue of bacterial infections in wound care for which there is currently no good solution. “Every year, nearly 10 million diabetics require lower limb amputation due to bacterial wound infections. Around 30% of diabetics die soon after the amputation. During the coronavirus pandemic, the number of amputations among diabetics increased tenfold, proving that home remedies for wound infection are indeed severely lacking. The problem of infection treatment clearly remains unsolved,” says the company’s CEO and Head of Technology Development Olesja Bondarenko.

“Silver and antibiotic-based products currently on the market are not effective enough to heal inflamed wounds. Wounds which are heavily infected with bacteria pose a particularly severe problem, especially if these wounds harbour bacteria that are difficult to treat, such as strains of Pseudomonas aeruginosa, and/or bacteria that are resistant to antibiotics. It is nearly impossible to treat such wounds. Our technology helps in these severe cases and also has a preventive antibacterial effect and promotes wound healing.”

Nanordica’s goal is to elevate the treatment of infected wounds to a new level and see their products become part of standard wound treatment guidelines.

Joining the Connected Health Cluster will allow Nanordica to work on the clinical and business development side of the company. “The technology at our disposal is excellent and the Cluster will hopefully help us reach as many strategic partners as possible. We want to gain new contacts through the Cluster, e.g. among clinical opinion leaders and pharmaceutical companies,” says Nanordica’s Head of Business Development Taavi Lipstok.

Nanordica Medical is alumni of the Tehnopol Startup Incubator programme and a member of Health Founders Accelerator.

Find more details about Nanordica Medical here.